Trial · NCT01703286
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28 | Linagliptin 5 mg | 0.885 | 90% Confidence Interval 0.695 to 1.128 | percentage | |
| Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28 | Glimepiride 1-4 mg | 1.002 | 90% Confidence Interval 0.795 to 1.262 | percentage | |
| Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28 | Placebo | 1.002 | 90% Confidence Interval 0.786 to 1.277 | percentage | |
| Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28 | Linagliptin 5 mg | 1.262 | 90% Confidence Interval 0.968 to 1.646 | Percentage | |
| Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28 | Glimepiride 1-4 mg | 1.045 | 90% Confidence Interval 0.815 to 1.339 | Percentage | |
| Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28 | Placebo | 1.009 | 90% Confidence Interval 0.777 to 1.311 | Percentage | |
| Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28 | Linagliptin 5 mg | 1.003 | 90% Confidence Interval 0.945 to 1.061 | percentage | |
| Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28 | Glimepiride 1-4 mg | 1.053 | 90% Confidence Interval 0.998 to 1.108 | percentage | |
| Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28 | Placebo | 0.981 | 90% Confidence Interval 0.923 to 1.039 | percentage | |
| Number of Patients With Adverse Events | Linagliptin 5 mg | 11 | participants | ||
| Number of Patients With Adverse Events | Glimepiride 1-4 mg | 25 | participants | ||
| Number of Patients With Adverse Events | Placebo | 14 | participants | ||
| Number of Patients With Adverse Events | REP - Linagliptin 5 mg | 4 | participants | ||
| Number of Patients With Adverse Events | REP - Glimepiride 1-4 mg | 7 | participants | ||
| Number of Patients With Adverse Events | Rep - Placebo | 7 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01703286/results